ADMA Biologics shares climb after third-quarter revenue and profit rise

what happened

Shares of ADMA Biologics jumped roughly 25% to $13.06 in morning trading after the company released third-quarter results above last year's levels, according to Dow Jones Newswires. The stock still sits 15% below its level of twelve months ago.

Quarterly revenue reached $141.1 million, up from $134.2 million. Net income came in at $49.9 million, or 22 cents per share, versus $36.4 million, or 15 cents, a year earlier, while adjusted earnings per share stood at 23 cents. Sales of Asceniv, the lead product, climbed 31% to $124.7 million, and Bivigam brought in $15.4 million.

For fiscal 2026, the company projects revenue of no less than $530 million and adjusted profit of $180 million or more.

why it matters

For investors, the report shows gains in both sales and profit, and the year-ahead outlook is framed as minimum levels. The rally of about a quarter in the shares, set against a 15% decline over the past year, suggests the market is reacting to the quarterly numbers rather than to a longer recovery trend.

market impact

ADMA Biologics shares: higher revenue and profit support the stock.

• ▲ADMA Biologics shares pressure up — third-quarter revenue and profit rose, and the annual outlook is set as minimum levels

tags

instruments